EASL Recommendations on Treatment of Hepatitis C 2016

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. The long-term impact of HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma (HCC). The number of chronically infected persons worldwide is estimated to be about 180 million, but most are unaware of their infection. Clinical care for patients with HCV-related liver disease has advanced considerably during the last two decades, thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention.

Download to read more.

Continue to send us your questions via Twitter and address your questions directly to Pr. Jean-Michel Pawlotsky.  @JMPawlotsky  #EASLiveChat   #HCV 

Panel Discussion

Debrief Recording of EASL Recommendations on Treatment of Hepatitis C 2016.

Watch Pr. Jean-Michel Pawlotsky review the highlights of EASL’s recommendations on treatment of Hepatitis C 2016.

Back to the list